Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Taneja

Showing results (81-90 of 845) with videos related to

Pageof 85
Sort By:
The Journal of Urology|August 22, 2015
Re: Complications following Surgery with or without Radiotherapy or Radiotherapy Alone for Prostate CancerSamir S Taneja
The Journal of Urology|August 22, 2015
Re: Postoperative Radiation Therapy for Patients at High-Risk of Recurrence after Radical Prostatectomy: Does Timing Matter?Samir S Taneja
The Journal of Urology|November 12, 2013
Re: Intermittent versus continuous androgen deprivation in prostate cancerSamir S Taneja
The Urologic Clinics of North America|November 25, 2017
Re-Creating the Urinary Tract: An Art Derived from ScienceSamir S Taneja
The Journal of Urology|May 15, 2012
Re: Is ultrasound imaging inferior to computed tomography or magnetic resonance imaging in evaluating renal mass size?Samir S Taneja
The Journal of Urology|May 15, 2012
Re: Accuracy of multi-detector computed tomography (MDCT) in staging of renal cell carcinoma (RCC): analysis of risk factors for mis-staging and its impact on surgical interventionSamir S Taneja
The Journal of Urology|June 17, 2017
Re: Diagnostic Accuracy of Multi-Parametric MRI and TRUS Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory StudySamir S Taneja
The Journal of Urology|January 25, 2015
Re: A phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy-Adjuvant versus Early Salvage (RAVES) trialSamir S Taneja
The Journal of Urology|January 25, 2015
Re: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancerSamir S Taneja
The Journal of Urology|August 2, 2016
Re: Risk Group and Death from Prostate Cancer: Implications for Active Surveillance in Men with Favorable Intermediate-Risk Prostate CancerSamir S Taneja
Pageof 85

Showing results (81-90 of 845) with videos related to

Sort By:
Pageof 85
The Journal of Urology|August 22, 2015
Re: Complications following Surgery with or without Radiotherapy or Radiotherapy Alone for Prostate CancerSamir S Taneja
The Journal of Urology|August 22, 2015
Re: Postoperative Radiation Therapy for Patients at High-Risk of Recurrence after Radical Prostatectomy: Does Timing Matter?Samir S Taneja
The Journal of Urology|November 12, 2013
Re: Intermittent versus continuous androgen deprivation in prostate cancerSamir S Taneja
The Urologic Clinics of North America|November 25, 2017
Re-Creating the Urinary Tract: An Art Derived from ScienceSamir S Taneja
The Journal of Urology|May 15, 2012
Re: Is ultrasound imaging inferior to computed tomography or magnetic resonance imaging in evaluating renal mass size?Samir S Taneja
The Journal of Urology|May 15, 2012
Re: Accuracy of multi-detector computed tomography (MDCT) in staging of renal cell carcinoma (RCC): analysis of risk factors for mis-staging and its impact on surgical interventionSamir S Taneja
The Journal of Urology|June 17, 2017
Re: Diagnostic Accuracy of Multi-Parametric MRI and TRUS Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory StudySamir S Taneja
The Journal of Urology|January 25, 2015
Re: A phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy-Adjuvant versus Early Salvage (RAVES) trialSamir S Taneja
The Journal of Urology|January 25, 2015
Re: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancerSamir S Taneja
The Journal of Urology|August 2, 2016
Re: Risk Group and Death from Prostate Cancer: Implications for Active Surveillance in Men with Favorable Intermediate-Risk Prostate CancerSamir S Taneja
Pageof 85